Rikke H. Olesen

Palle Juul Jensens Boulevard 99
Aarhus N, 8200, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 47 publications

TCR bias drives development of dominant vaccine-induced CD8+ T cell responses which can be redirected toward cellular targets.

TCR bias drives development of dominant vaccine-induced CD8+ T cell responses which can be redirected toward cellular targets.

Journal: Vaccine

Published: June 30, 2025

Autologous neutralizing antibodies and polyfunctional T cells contribute to long-term HIV-1 post-intervention control.

Autologous neutralizing antibodies and polyfunctional T cells contribute to long-term HIV-1 post-intervention control.

Journal: Nature immunology

Published: June 04, 2025

Helminth extracellular vesicles co-opt host monocytes to drive T cell anergy.

Helminth extracellular vesicles co-opt host monocytes to drive T cell anergy.

Journal: Journal of extracellular vesicles

Published: July 05, 2024

Longitudinal Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Immunity Over 2 Years Following Vaccination and Infection.

Longitudinal Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Immunity Over 2 Years Following Vaccination and Infection.

Journal: The Journal of infectious diseases

Published: January 05, 2024

TLR9 agonism differentially impacts human NK cell-mediated direct killing and antibody-dependent cell-mediated cytotoxicity.

TLR9 agonism differentially impacts human NK cell-mediated direct killing and antibody-dependent cell-mediated cytotoxicity.

Journal: Scientific reports

Published: November 06, 2023

Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study.

Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study.

Journal: BMC immunology

Published: August 29, 2023

Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial.

Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial.

Journal: Nature medicine

Published: May 16, 2023

Revaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patients.

Revaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patients.

Journal: Clinical and experimental rheumatology

Published: April 16, 2023

Single cell analysis reveals a subset of cytotoxic-like plasmacytoid dendritic cells in people with HIV-1.

Single cell analysis reveals a subset of cytotoxic-like plasmacytoid dendritic cells in people with HIV-1.

Journal: iScience

Published: April 06, 2023

Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity.

Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity.

Journal: Nature communications

Published: August 15, 2022

Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunity.

Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunity.

Journal: Communications medicine

Published: June 30, 2022

CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist Immunotherapy.

CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist Immunotherapy.

Journal: Frontiers in cellular and infection microbiology

Published: April 13, 2022

Showing 1-12 of 47

Last Updated: 09/26/2026